Foghorn Therapeutics
FHTX
60 hedge funds and large institutions have $163M invested in Foghorn Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 10 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0.3% more ownership
Funds ownership: 62.43% → 62.73% (+0.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $166M → $163M (-$3.72M)
8% less funds holding
Funds holding: 65 → 60 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
82% less call options, than puts
Call options by funds: $3K | Put options by funds: $17K
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$1.36M |
| 2 |
Millennium Management
New York
|
-$955K |
| 3 |
GW
GW & Wade
Wellesley,
Massachusetts
|
-$688K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$670K |
| 5 |
RWM
Rockwood Wealth Management
New Hope,
Pennsylvania
|
-$400K |
FHTX Hedge Fund Activity: Q1 2023 in Review
60 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2023, worth a combined $163M — down 2.2% from $166M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FHTX and 5 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was Raymond James & Associates, adding an estimated $3.49M. The largest seller was Morgan Stanley, cutting an estimated $1.36M.
- 60 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2023, down from 65 in Q4 2022.
- Funds reported $163M of Foghorn Therapeutics stock for Q1 2023, down 2.2% quarter-over-quarter.
- 5 funds opened new Foghorn Therapeutics positions in Q1 2023 and 10 closed out, a net change of -5 holders.
- The largest Foghorn Therapeutics buyer in Q1 2023 was Raymond James & Associates, an estimated $3.49M added.
- The largest Foghorn Therapeutics seller in Q1 2023 was Morgan Stanley, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2023.